Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
Open Access
- 29 January 2008
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (4) , 832-839
- https://doi.org/10.1038/sj.bjc.6604211
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinomaAnnals of Oncology, 2007
- Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer PatientsClinical Cancer Research, 2005
- Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patientsPharmacogenetics, 2004
- Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient DataJournal of Clinical Oncology, 2004
- Cancer pharmacogenetics: polymorphisms, pathways and beyondNature Reviews Cancer, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5-FluorouracilJapanese Journal of Cancer Research, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal Of Cancer, 1998
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1978